overweight
For more than a year, there has been a rising trend in using diabetes drugs such as Ozempic solely for its weight loss effect. As with any medication, there are potential risks of side effects that you may or may not have been aware of initially. For instance, in 2023, American Jaclyn Bjorklund launched legal proceedings against Novo Nordisk and Eli Lilly and Co, the manufacturers of Ozempic and Mounjaro respectively, alleging severe gastrointestinal complications, particularly gastroparesis characterised by a paralysis of the stomach. Ozempic: How a TikTok weight loss trend caused a global di...
Euronews (English)
The weight-loss drug semaglutide - commonly sold under the brand names Ozempic and Wegovy - reduced cardiovascular events such as stroke and heart attack in adults with preexisting disease independent of weight loss. It also helped people keep their weight down for at least four years. That is according to two new analyses of a large trial presented at the European Congress on Obesity in Venice on Monday. Semaglutide is the main active ingredient in the popular weight-loss jabs Ozempic and Wegovy. It mimics the GLP-1 hormone which can signal that your body is full. The analyses looked at the S...
Euronews (English)
Danish pharmaceutical powerhouse Novo Nordisk has emerged as one of the standout performers among European mega-cap stocks in the early months of this year, boasting a robust 25% surge year to date. This performance further cemented Novo Nordisk's status as the largest European company by market capitalisation, reaching almost €550 billion and outpacing the market value of Tesla. Over the past year, the Danish pharma titan has seen its price jump by 80%, a rate of increase unmatched by any other European company valued at €100 billion or more. Novo Nordisk's growth driver: Weight-loss drug Weg...
Euronews (English)
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら